1. Home
  2. CUE vs CLIR Comparison

CUE vs CLIR Comparison

Compare CUE & CLIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.62

Market Cap

17.6M

Sector

Health Care

ML Signal

HOLD

Logo ClearSign Technologies Corporation (DE)

CLIR

ClearSign Technologies Corporation (DE)

HOLD

Current Price

$5.33

Market Cap

33.3M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
CLIR
Founded
2014
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
17.6M
33.3M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
CUE
CLIR
Price
$0.62
$5.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$20.00
AVG Volume (30 Days)
19.4M
59.4K
Earning Date
05-11-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
N/A
EPS
N/A
N/A
Revenue
$27,466,000.00
$530,000.00
Revenue This Year
N/A
$89.55
Revenue Next Year
N/A
$70.23
P/E Ratio
N/A
N/A
Revenue Growth
195.75
N/A
52 Week Low
$0.17
$0.39
52 Week High
$1.03
$7.56

Technical Indicators

Market Signals
Indicator
CUE
CLIR
Relative Strength Index (RSI) 72.18 60.96
Support Level $0.24 $0.58
Resistance Level $0.66 $7.56
Average True Range (ATR) 0.11 0.87
MACD 0.05 -0.09
Stochastic Oscillator 70.92 48.89

Price Performance

Historical Comparison
CUE
CLIR

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About CLIR ClearSign Technologies Corporation (DE)

ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.

Share on Social Networks: